[go: up one dir, main page]

UY39479A - Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo - Google Patents

Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo

Info

Publication number
UY39479A
UY39479A UY0001039479A UY39479A UY39479A UY 39479 A UY39479 A UY 39479A UY 0001039479 A UY0001039479 A UY 0001039479A UY 39479 A UY39479 A UY 39479A UY 39479 A UY39479 A UY 39479A
Authority
UY
Uruguay
Prior art keywords
preparing
same
benzimidazole
procedure
compound derived
Prior art date
Application number
UY0001039479A
Other languages
English (en)
Inventor
Eun Kyung Jeon
Young Dae Cho
Min Jung Kim
Sun Young Park
Da Som Lim
Tae Keun Cho
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of UY39479A publication Critical patent/UY39479A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un comprimido de desintegración oral que incluye un compuesto derivado de benzimidazol y un procedimiento de preparación del mismo.
UY0001039479A 2020-10-23 2021-10-21 Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo UY39479A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200138712 2020-10-23

Publications (1)

Publication Number Publication Date
UY39479A true UY39479A (es) 2021-11-30

Family

ID=79283599

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039479A UY39479A (es) 2020-10-23 2021-10-21 Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo

Country Status (11)

Country Link
US (1) US20230381109A1 (es)
EP (1) EP4232001A4 (es)
JP (2) JP7626914B2 (es)
KR (2) KR102748218B1 (es)
CN (1) CN116507318A (es)
AR (1) AR123872A1 (es)
AU (1) AU2021364255B2 (es)
CA (1) CA3196459A1 (es)
MX (1) MX2023004611A (es)
UY (1) UY39479A (es)
WO (1) WO2022086238A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025002519A1 (en) * 2023-06-29 2025-01-02 Fertin Pharma A/S Oral tablet with improved uniformity of content of actives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084527B (en) * 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
CA2631880C (en) 2005-12-19 2011-03-29 Pfizer Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
US20090258897A1 (en) 2008-04-11 2009-10-15 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
EP2452680B1 (en) 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
CN108012527A (zh) * 2015-06-08 2018-05-08 Cj医药健康株式会社 苯并咪唑衍生物用于夜间酸突破的用途
KR101829706B1 (ko) 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
KR101849125B1 (ko) * 2016-12-12 2018-04-16 동화약품주식회사 프로톤 펌프 저해제를 포함하는 고체 분산체, 이의 제조방법 및 이를 포함하는 구강 붕해정
KR101960357B1 (ko) * 2016-12-26 2019-03-20 씨제이헬스케어 주식회사 벤즈이미다졸 유도체를 포함하는 신규한 제제
JOP20190198A1 (ar) 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
WO2020210878A1 (en) 2019-04-18 2020-10-22 Borody Thomas J Compositions and methods for treating, ameliorating and preventing h. pylori infections

Also Published As

Publication number Publication date
EP4232001A4 (en) 2024-09-18
MX2023004611A (es) 2023-05-08
CA3196459A1 (en) 2022-04-28
EP4232001A1 (en) 2023-08-30
AU2021364255A1 (en) 2023-06-22
KR20250004202A (ko) 2025-01-07
JP2025038168A (ja) 2025-03-18
JP7626914B2 (ja) 2025-02-05
US20230381109A1 (en) 2023-11-30
AU2021364255A9 (en) 2024-06-27
AU2021364255B2 (en) 2025-02-13
WO2022086238A1 (en) 2022-04-28
KR102748218B1 (ko) 2024-12-31
JP2023547092A (ja) 2023-11-09
AR123872A1 (es) 2023-01-18
CN116507318A (zh) 2023-07-28
KR20220054211A (ko) 2022-05-02

Similar Documents

Publication Publication Date Title
CO2021003074A2 (es) Derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona y compuestos relacionados como inhibidores de ptpn11 (shp2) para el tratamiento del cáncer
ECSP21027049A (es) Inhibidores de la proteína tirosina fosfatasa
CL2019003632A1 (es) Síntesis de derivados fosfatos.
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
MA43518B1 (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
CO2018008759A2 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2019003281A1 (es) Derivados de piperidina. (divisional solicitud 201900169)
BR112022008294A2 (pt) Composições de profármaco e métodos de tratamento
MX373363B (es) Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
BR112021024431A2 (pt) Inibidores da via de resposta ao estresse integrada
UY39479A (es) Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo
CL2019000573A1 (es) Composiciones para comprimidos.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CL2018001541A1 (es) Sintesis diastereoselectivo de derivados de fosfato y de profármaco gemcitabina nuc-1031.
CL2022001173A1 (es) Forma cristalina de la base libre de un receptor del componente c5a del complemento
TR201905298T4 (tr) Turunçgillerden tekstil üretimi.
PH12017502249A1 (en) Tofacitinib orally disintegrating tablets
EA201990198A1 (ru) Радиолиганды для визуализации фермента ido1
BR112017002859A2 (pt) peça de sinterização, câmara de sinterização e programa de computador
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
DOP2022000130A (es) Derivados de benzimidazol
MX2021001562A (es) Excipiente de alto rendimiento que comprende celulosa microcristalina co-procesada y carbonato de calcio reaccionado en superficie.
NZ703549A (en) Benzodioxole derivative and preparation method and use thereof